explore -WSS

explore

author：explore 2025-09-29 01:35:23 - browse：158

Photo of an arrangement of aspirin pills — Patrick Sison/AP

Low-dose aspirin led to a reduction in liver fat among patients with metabolic-associated liver disease, a small study out of Boston found.

The clinical trial, led by Tracey Simon of Massachusetts General Hospital and Harvard Medical School, compared two groups of patients with metabolic dysfunction-associated steatotic liver disease, or MASLD. One group was given baby aspirin daily for six months, while the other received a placebo pill. At the end of the study period, the aspirin group had reduced hepatic fat content while the placebo group had higher fat buildup.

MASLD (formerly known as non-alcoholic fatty liver disease) is a growing health threat, with 1 in 3 Americans having a troublesome amount of fat in their liver. The lipid buildup feeds into a toxic cycle of inflammation, tissue damage and, ultimately, irreversible scarring.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： The Biogen Aduhelm mess could happen again

hotspot

entertainment

WSS

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Readout Newsletter: Amgen, Regeneron, BGI Group and more

STAT Madness 2024: Meet the contenders

NEJM study measures Covid brain fog, impact on IQ

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Medicare Advantage isn’t working — for anyone

Wikipedia

explore

knowledge

Heart attack and stroke risk calculators need revising

Study fuels hope CAR

Apple is now the first public company to be valued at $3 trillion

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

United colonoscopy coverage change 'may cost lives,' doctors say

A single Democrat is willing to weaken Medicare negotiation power

Jerome Adams on the need for new antivirals for Covid

Elisabeth Bik tackles the widespread issue of research misconduct

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

entertainment

Redefining sustainability for the pharmaceutical industry

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

Global cancer cases to surge 77% by 2050, WHO report says

Laying a path for careers in science

Unique patient identifier: Experts argue the benefits, pitfalls

Color Health wants to make cancer screenings convenient

hotspot

entertainment

hotspot

Wikipedia